Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355763 | 0.83 | IDO1 (0.44) | IDO1ALDH1A1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4902296 | 0.75 | TBXAS1 (0.68) | ALDH1A1TBXAS1KDM4E | |
| SCHEMBL5704638 | 0.75 | KCNA3 (0.42) | ALDH1A1THRBKDM4EMAPTRAB9A | |
| SCHEMBL12269283 | 0.74 | THRB (0.45) | IDO1ALDH1A1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL3861581 | 0.74 | LTA4H (0.45) | IDO1ALDH1A1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL10785391 | 0.74 | THRB (0.48) | IDO1ALDH1A1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL15300912 | 0.74 | MAPK1 (0.55) | IDO1ALDH1A1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL11866 | 0.73 | KMT2A (0.56) | ALDH1A1KDM4EMAPTLMNANPC1 | |
| SCHEMBL129009 | 0.72 | KMT2A (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6292244 | 0.71 | KMT2A (0.60) | ALDH1A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| EP-1694638-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | IDO1 751/4885ALDH1A1 425/4885PRKAB2 4721/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | IDO1 722/4885ALDH1A1 425/4885PRKAB2 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.